预约演示
更新于：2025-05-08
Posaconazole
泊沙康唑
更新于：2025-05-08
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C37H42F2N8O4 |
InChIKeyRAGOYPUPXAKGKH-XAKZXMRKSA-N |
CAS号171228-49-2 |
关联
174
项与 泊沙康唑 相关的临床试验ChiCTR2500101166
Establishment of Population Pharmacokinetic Model of Posaconazole in Patients with Invasive Fungal Diseases and Development of Intelligent and Precise Cinical Decision System
ChiCTR2500098742
A multicenter, randomized controlled phase II clinical study of oral posaconazole combined with chemotherapy and PD-1 inhibitors as neoadjuvant treatment for early or locally advanced triple-negative breast cancer
CTR20250761
泊沙康唑口服混悬液在健康受试者中进行的单中心、单剂量、2制剂、4周期、2序列、开放、随机、完全重复交叉的生物等效性试验。
100 项与 泊沙康唑 相关的临床结果
登录后查看更多信息
100 项与 泊沙康唑 相关的转化医学
登录后查看更多信息
100 项与 泊沙康唑 相关的专利（医药）
登录后查看更多信息
5,134
项与 泊沙康唑 相关的文献（医药）2025-12-31Emerging Microbes & Infections
Emerging antifungal resistance in
Trichophyton mentagrophytes
: insights from susceptibility profiling and genetic mutation analysis
Article
作者: Richardson, Malcolm ; Bai, Lin ; Richardson, Riina ; Shao, Jin ; Shao, Yakun ; Wan, Zhe ; Yu, Jin ; Song, Yinggai ; Verweij, Paul ; Li, Ruoyu ; de Hoog, Sybren
ABSTRACTTrichophyton species, the leading cause of dermatophytosis globally, are increasingly resistant to antifungal treatments, concerns about effective management strategies. In light of the absence of established resistance criteria for terbinafine and azoles, coupled with a dearth of research on resistance mechanisms in Trichophyton, antifungal susceptibility and drug resistance gene diversity were analyzed across 64 T. mentagrophytes, 65 T. interdigitale, and 2 T. indotineae isolates collected in China between 1999 and 2024 and 101 published T. indotineae strains. Analyses of the minimum inhibitory concentrations (MICs) of terbinafine, itraconazole, voriconazole, posaconazole, and isavuconazole revealed a concerning increase in T. indotineae with terbinafine resistance, including two novel isolates from China. Compared with T. interdigitale, T. mentagrophytes presented higher terbinafine MICs but similar azole susceptibility. Notably, 27 T. interdigitale isolates were classified as non-wild-type for terbinafine. Genetic diversity was analyzed for the SQLE, CYP51A and CYP51B gene. Specifically, T. indotineae isolates presented SQLE protein changes linked to terbinafine resistance. SQLE diversity was linked to terbinafine sensitivity, whereas alterations in CYP51A were associated with itraconazole sensitivity, with notable statistical significance evident across various protein isoforms. The relationship between protein diversity and drug sensitivity is presented in detail. Together, these findings highlight a growing prevalence of antibiotic resistance among Trichophyton and identify potential target genes for new therapies, underscoring the need for ongoing monitoring and offering directions for novel therapeutics.
2025-07-01INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Posaconazole effectiveness in rare invasive fungal infections: A systematic literature review
Review
作者: Simon, Alyssa ; Campbell, Havilland ; Bernauer, Mark ; Kaminski, Allysen ; Cossrow, Nicole ; Patel, Dipen ; Waskin, Hetty
INTRODUCTION:
Mucormycosis, hyalohyphomycosis, chromoblastomycosis, and fungal mycetoma are rare invasive fungal infections (IFIs) that cause significant morbidity and mortality in immunocompromised patients. Few effective treatment options are available for these IFIs.
METHODS:
We performed a systematic literature review of MEDLINE and Embase to identify studies published from 2005 (year of posaconazole approval) to 22 October 2022, reporting the efficacy/effectiveness of posaconazole monotherapy or combination therapy for treating mucormycosis, hyalohyphomycosis, chromoblastomycosis, and mycetoma. Positive outcomes or positive clinical outcomes were defined as reporting of a positive efficacy/effectiveness measure (i.e. no relapse, response, cure, radiological improvement, clinical/symptom improvement, or survived therapy).
RESULTS:
Of 3207 articles identified (after removing duplicates), 533 articles (mostly case reports) were included. Positive clinical outcomes with posaconazole therapy were observed in most patients with mucormycosis (74.8%, 1197/1601), hyalohyphomycosis (58.5%, 62/106), chromoblastomycosis (90.5%, 19/21), and mycetoma (100%, 5/5). Overall survival was around 70% or greater across the IFIs examined. Positive response was higher in second-line monotherapy than first-line monotherapy in mucormycosis and chromoblastomycosis. Higher mortality was observed with combination therapy than monotherapy in mucormycosis and hyalohyphomycosis infections (except for first-line use in mucormycosis). Positive clinical outcome was 78.6% and overall survival was 78.6% in 323 coronavirus disease-associated mucormycosis infection cases.
CONCLUSIONS:
Despite the rarity of these IFIs, substantial data have been published since posaconazole was initially approved in 2005, and the real-world case reports demonstrate that posaconazole is an effective therapeutic option alone or in combination for the treatment of these rare IFIs.
2025-06-01Journal of Stomatology Oral and Maxillofacial Surgery
Delayed maxillary reconstruction following mucormycosis: A comprehensive analysis of surgical strategies and outcomes
Article
作者: Garg, Paheli ; Goil, Pradeep ; Charan Pahari, Dr Kaushal ; Charan Pahari, Kaushal ; Goil, Dr Pradeep ; Vashistha, Aakansha ; Vashistha, Dr Aakansha ; Garg, Dr Paheli
STUDY DESIGN:
This study is a prospective observational study conducted over two years from December 2020 to March 2023 at the Department of Plastic and Reconstructive Surgery.
OBJECTIVE:
To evaluate the outcomes of delayed reconstruction in patients with maxillectomy defects post-COVID-19 associated mucormycosis, focusing on safety, morbidity, and aesthetic results.
METHODS:
Fifty patients with post-COVID-19 mucormycosis and maxillectomy defects without skin involvement were included. These patients underwent radical debridement and were treated with Amphotericin B followed by Posaconazole therapy until clinical and radiological resolution of the disease. Reconstruction was performed after a minimum of six months post-maxillectomy. Flaps used for reconstruction included the radial forearm free flap (RAFF), anterolateral thigh flap (ALT), and free fibula osteomyocutaneous flap, planned using a 3D-printed model. Follow-up was conducted weekly for the first month and monthly for the next two months, with semiannual visits thereafter.
RESULTS:
Of the 50 patients, 42 % were male, and 58 % were female, with a mean age of 43 ± 8.75 years. Most patients (88 %) were diabetic. Maxillectomy defects were categorized as type IIA, IIB, IIIA, IIIB, and IV based on the Cordeiro classification. Four flaps (8 %) required re-exploration, with three salvaged. Complications included marginal flap necrosis (4 %) and oro-nasal fistula (2 %). The average hospital stay was six days, extended to ten days for re-explored cases. Flap dimensions varied with the largest being 62 cm² for the free fibula flap.
CONCLUSIONS:
Delayed reconstruction using free flaps in patients with post-COVID-19 mucormycosis maxillectomy defects without skin involvement is a safe approach with minimal morbidity. This method allows confirmation of disease resolution before major reconstructive surgery, resulting in excellent aesthetic and functional outcomes.
100 项与 泊沙康唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 毛霉菌感染 | 日本 | 2020-01-23 | |
| 曲霉菌病 | 中国 | 2013-06-03 | |
| 念珠菌病 | 美国 | 2006-09-15 | |
| 侵袭性真菌感染 | 澳大利亚 | 2006-03-15 | |
| 接合菌病 | 澳大利亚 | 2006-03-15 | |
| 着色霉菌病 | 欧盟 | 2005-10-25 | |
| 着色霉菌病 | 欧盟 | 2005-10-25 | |
| 着色霉菌病 | 冰岛 | 2005-10-25 | |
| 着色霉菌病 | 冰岛 | 2005-10-25 | |
| 着色霉菌病 | 列支敦士登 | 2005-10-25 | |
| 着色霉菌病 | 列支敦士登 | 2005-10-25 | |
| 着色霉菌病 | 挪威 | 2005-10-25 | |
| 着色霉菌病 | 挪威 | 2005-10-25 | |
| 球孢子菌病 | 欧盟 | 2005-10-25 | |
| 球孢子菌病 | 欧盟 | 2005-10-25 | |
| 球孢子菌病 | 冰岛 | 2005-10-25 | |
| 球孢子菌病 | 冰岛 | 2005-10-25 | |
| 球孢子菌病 | 列支敦士登 | 2005-10-25 | |
| 球孢子菌病 | 列支敦士登 | 2005-10-25 | |
| 球孢子菌病 | 挪威 | 2005-10-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 深部真菌病 | 临床3期 | - | 2014-07-29 | |
| 侵袭性肺曲霉菌病 | 临床3期 | - | 2013-09-25 | |
| 白细胞减少 | 临床3期 | - | 2008-11-01 | |
| 急性髓性白血病 | 临床3期 | - | 2002-07-01 | |
| 骨髓增生异常综合征 | 临床3期 | - | 2002-07-01 | |
| 中性粒细胞减少 | 临床3期 | - | 2002-07-01 | |
| 口腔念珠菌病 | 临床3期 | 美国 | 1998-08-01 | |
| 口腔念珠菌病 | 临床3期 | 巴巴多斯 | 1998-08-01 | |
| HIV感染 | 临床3期 | 美国 | 1998-08-01 | |
| HIV感染 | 临床3期 | 巴巴多斯 | 1998-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 88 | standard of care (SOC)+Posaconazole (SOC + 'Posaconazole 18 MG/ML') | 選衊鏇襯選廠餘齋鏇鬱 = 襯窪醖遞艱觸夢夢鹽觸 簾築積築廠餘鏇蓋鬱蓋 (積顧遞積淵衊觸積簾廠, 齋餘鹽簾觸醖餘齋鬱網 ~ 鏇範鹹積鹽夢窪糧憲糧) 更多 | - | 2025-04-08 | ||
standard of care (SOC) (Standard of Care) | 選衊鏇襯選廠餘齋鏇鬱 = 膚選築簾鹽願齋築膚鬱 簾築積築廠餘鏇蓋鬱蓋 (積顧遞積淵衊觸積簾廠, 築積網廠構糧積網顧觸 ~ 鹽繭窪顧選蓋築廠遞鏇) 更多 | ||||||
临床2期 | 10 | 範鑰襯範憲淵簾膚鏇鹽 = 選襯獵鏇夢遞齋夢糧衊 廠鏇構範簾獵積壓獵繭 (窪鬱窪鹽積鑰構廠齋壓, 蓋獵衊餘製遞糧壓顧構 ~ 網願蓋鏇鬱襯憲鬱選顧) 更多 | - | 2025-01-22 | |||
临床2期 | 31 | (Age Cohort 1 (2 -< 12 Years Old)) | 選齋簾醖壓淵簾遞醖顧 = 簾願遞積廠廠窪齋觸築 窪衊簾鹹製襯築衊鏇淵 (襯鬱構餘顧窪壓壓夢獵, 糧築構積鹹選齋齋壓膚 ~ 襯築積窪獵糧夢鹽鏇築) 更多 | - | 2025-01-14 | ||
(Age Cohort 2 (12 -< 18 Years Old)) | 選齋簾醖壓淵簾遞醖顧 = 願製簾餘壓糧醖簾襯醖 窪衊簾鹹製襯築衊鏇淵 (襯鬱構餘顧窪壓壓夢獵, 壓繭齋範願築鹽範憲範 ~ 齋淵蓋觸觸鹹襯襯衊觸) 更多 | ||||||
N/A | - | 構鹽淵積襯築壓艱範積(鹽網願壓憲顧廠夢鹽鹽) = 選構鑰積獵簾構餘蓋積 衊艱淵壓醖糧築鑰蓋憲 (鬱鑰齋鬱鹹鏇蓋壓齋繭 ) | 积极 | 2025-01-01 | |||
No antifungal prophylaxis | 構鹽淵積襯築壓艱範積(鹽網願壓憲顧廠夢鹽鹽) = 壓鏇選廠廠構築蓋構範 衊艱淵壓醖糧築鑰蓋憲 (鬱鑰齋鬱鹹鏇蓋壓齋繭 ) | ||||||
临床2期 | 20 | 鹹願顧鬱衊淵淵願簾窪 = 夢艱獵製積艱願觸願鑰 鑰鏇製觸構觸顧繭繭顧 (壓鏇膚鹹壓鹹淵壓壓窪, 窪鏇觸繭構遞鹹憲鹹鬱 ~ 窪襯鹽繭醖製製範窪憲) 更多 | - | 2024-12-20 | |||
N/A | - | 觸鹹憲觸鹹築廠鑰網憲(憲餘憲網繭築糧積製網) = There were no significant differences in survival outcomes, in months, including PFS (5.7 vs 4.2, p=0.53) 觸窪範憲鑰構觸淵鏇鏇 (艱簾醖選築積醖膚鑰積 ) 更多 | - | 2024-12-07 | |||
临床2期 | 20 | Posaconazole 300mg twice daily | 範構鹽窪獵遞範憲範願(繭鹽壓壓繭襯遞餘鹽構) = 廠願憲簾鹹鏇鑰鹹襯艱 夢鬱糧積糧蓋獵網鏇鑰 (觸餘網醖顧築積構鹽鹹 ) 更多 | 积极 | 2024-05-14 | ||
N/A | 94 | 壓壓壓觸觸糧觸憲廠積(簾選廠膚簾範窪顧憲醖) = 網憲範齋齋餘遞糧簾廠 範選齋獵憲範醖鏇憲選 (鹽鏇製鏇積築淵壓鹽艱 ) 更多 | 积极 | 2024-05-14 | |||
No posaconazole prophylaxis | 壓壓壓觸觸糧觸憲廠積(簾選廠膚簾範窪顧憲醖) = 齋艱夢醖鑰醖鏇壓鏇遞 範選齋獵憲範醖鏇憲選 (鹽鏇製鏇積築淵壓鹽艱 ) 更多 | ||||||
N/A | - | Posaconazole gastro-resistant tablets | 遞齋鏇衊衊鏇築夢遞憲(鏇製壓鏇繭艱齋鬱淵鏇) = 範衊製糧窪積糧簾築襯 顧廠鬱糧膚選膚鹹窪繭 (膚獵壓範鏇網繭製廠顧 ) 更多 | - | 2024-05-14 | ||
Other antifungal prophylaxis | 遞齋鏇衊衊鏇築夢遞憲(鏇製壓鏇繭艱齋鬱淵鏇) = 糧製觸繭遞窪齋獵窪襯 顧廠鬱糧膚選膚鹹窪繭 (膚獵壓範鏇網繭製廠顧 ) | ||||||
N/A | 143 | 簾鏇衊壓鏇鹹蓋願艱築(廠艱網襯築觸壓顧選選) = 簾淵夢窪襯積衊顧網觸 餘廠齋廠鬱衊蓋齋醖願 (選醖衊餘夢製淵襯繭膚 ) | - | 2023-12-10 | |||
簾鏇衊壓鏇鹹蓋願艱築(廠艱網襯築觸壓顧選選) = 鹹鬱蓋簾鹹構艱淵觸鹽 餘廠齋廠鬱衊蓋齋醖願 (選醖衊餘夢製淵襯繭膚 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用